Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms Archway
- Sponsors Roche
- 25 Oct 2019 Planned End Date changed from 26 May 2022 to 26 Apr 2021.
- 25 Oct 2019 Planned primary completion date changed from 28 Feb 2021 to 31 Mar 2020.
- 25 Oct 2019 Status changed from recruiting to active, no longer recruiting.